Company news
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news
Xenon Pharmaceuticals Inc. news releases on 6ix. Latest, Nov 9, 2022: Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Press releases — page 3
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
November 8, 2022
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
November 6, 2022
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
November 2, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
October 31, 2022
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
August 31, 2022
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022
Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 7, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
August 1, 2022
Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
July 10, 2022
Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 26, 2022
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
June 21, 2022
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
June 21, 2022
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
June 20, 2022
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
May 2, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update
May 2, 2022
Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 3, 2022
Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days
March 21, 2022
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
February 28, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
February 21, 2022
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 13, 2022
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
January 11, 2022
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
January 9, 2022
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)
December 2, 2021
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
December 2, 2021
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
November 2, 2021
Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 7, 2021
Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
October 4, 2021
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
October 3, 2021
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
October 2, 2021
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
September 7, 2021
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
August 22, 2021
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021
Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
August 9, 2021
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
August 3, 2021
Xenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021
July 12, 2021
Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders
July 6, 2021
Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders
June 2, 2021
Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 30, 2021
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
May 3, 2021
Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
March 28, 2021
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 11, 2021
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
March 8, 2021
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
March 8, 2021
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
March 7, 2021
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
February 28, 2021